I am a breastfeeding mother and i want to know if it is safe to use ORG 2969? Is ORG 2969 safe for nursing mother and child? Does ORG 2969 extracts into breast milk? Does ORG 2969 has any long term or short term side effects on infants? Can ORG 2969 influence milk supply or can ORG 2969 decrease milk supply in lactating mothers?
- DrLact safety Score for ORG 2969 is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of ORG 2969 is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that ORG 2969 does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of ORG 2969 safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
ORG 2969 (Progestogen-only contraceptive pill) that does not alter quality or composition of breast milk. Excretion into breast milk is non-significant, with no harmful effects on breastfed infants from treated mother reported. Within the first 6 weeks after birth, non-hormonal contraceptive methods are preferred.
ORG 2969 is only available in the United States in combination oral contraceptive products containing 150 mcg of ORG 2969 and 30 mcg of ethinyl estradiol. Based on the available evidence, expert opinion holds that nonhormonal methods are preferred during breastfeeding and progestin-only contraceptive are preferred over combined oral contraceptives in breastfeeding women, especially during the first 4 weeks postpartum. For further information, consult the record entitled, "Contraceptives, Oral, Combined."
A nonblinded, nonrandomized study compared oral ORG 2969 75 mcg alone daily (n = 42) to an intrauterine device (IUD; n = 40) begun 28 to 56 days postpartum for contraception. No differences in infant length, weight or biparietal head circumferences were found after 1, 4, and 7 treatment cycles. Temporary breast enlargement was reported in 2 infants and increased sweating was reported in 1 infant in the ORG 2969 group, compared with no adverse effects reported in infants in the IUD group. The growth of some infants were again measured at 1.5 and 2.5 years; no clinically important differences were found.[1] A breastfed (extent not stated) infant developed scrotal hair at 4 months of age. His mother had received the progestin, dydrogestrone, during the first trimester of pregnancy and began taking ORG 2969 0.075 mg daily as a contraceptive beginning at 3 months postpartum. His mother discontinued ORG 2969 after 28 days and the scrotal hair resolved by 11 months of age. ORG 2969 was a possible contributing cause of scrotal hair growth in this infant.[2]
A nonblinded, nonrandomized study compared oral ORG 2969 75 mcg alone daily (n = 42) to an intrauterine device (n = 40) begun 28 to 56 days postpartum for contraception. During the 7-month trial period, 1 woman dropped out of the trial because of diminished lactation compared with none in the IUD group. At the end of the first and fourth treatment cycle, there were no differences in the amount of milk produced between the ORG 2969 and IUD groups. No differences in triglyceride, protein or lactose content of milk were found at the end of 1, 4, and 7 cycles of therapy.[1] A nonrandomized study followed 200 women given a ORG 2969-only contraceptive 75 mcg daily for 6 months beginning at 6 weeks postpartum and compared them to 200 women who received placebos. No difference was found in the amounts of milk production or infant growth and development between the two groups.[3]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.